Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
The purpose of this study is to study a new treatment for HER-2/neu (+) breast cancer.
Breast Cancer
BIOLOGICAL: trastuzumab|DRUG: cyclophosphamide|DRUG: doxorubicin hydrochloride|DRUG: lapatinib ditosylate|DRUG: paclitaxel|OTHER: laboratory biomarker analysis
Number of Patients Who Completed All Planned Therapy, The number of patients who completed all planned therapy (dose-dense adjuvant/ neoadjuvant chemotherapy regimen) in HER-2/neu-overexpressed/ amplified breast cancer patients., 2 years
Number of Patients Who Were Evaluated for Toxicity, Please see adverse event section in the results. Toxicities were assessed by the National Cancer Institute Common Toxicity Criteria (NCI CTC) version 3.0., 2 years
The purpose of this study is to study a new treatment for HER-2/neu (+) breast cancer.